![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1444206
¼¼°è º´¿ø³» °¨¿° ´ëÃ¥ ½ÃÀå : Á¡À¯À² ºÐ¼®, ¾÷°è µ¿Çâ°ú Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)Global Hospital Acquired Infection Control - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) |
¼¼°è º´¿ø³» °¨¿° ´ëÃ¥ ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 42¾ï 6,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2029³â±îÁö 51¾ï 8,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£(2024-2029³â) µ¿¾È 3.97%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
COVID-19ÀÇ Àü¿°º´Àº º´¿ø °¨¿°ÀÇ ¼ö¸¦ ÁÙÀ̱â À§ÇØ ¼¼°è º¸°Ç±â±¸ ¹× Áúº´ °ü¸® ¿¹¹æ ¼¾ÅÍ(CDC)°¡ ±ÇÀåÇÏ´Â °Íó·³ ¼Õ À§»ý ¹× ÀüÅëÀûÀÎ °¨¿° Á¦¾î ¹æ¹ýÀ» »ç¿ëÇÏ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÀÏÀ» °Á¶Çß½À´Ï´Ù. °Ô´Ù°¡ 2021³â 9¿ù¿¡ ¹ßÇ¥µÈ ¡¸¿ø³» °¨¿°ÀÇ ¿¹¹æ: COVID-19 ÆÒµ¥¹Í½ÃÀÇ ±¸¼º¡¹À̶ó°í Á¦¸ñÀ» ºÙÀÎ ±â»ç¿¡¼´Â ÀεµÀÇ ºñÇϸ£ÁÖ¿¡¼ 2019³â 1¿ùºÎÅÍ 2020³â 12¿ù±îÁö µ¥ÀÌÅͰ¡ ´ëÁ¶µÇ¾î, Ä«Å×ÅÍ °ü·Ã ¿ä·Î¿¡ ´ëÇÑ µ¥ÀÌÅͰ¡ ¼öÁýµÇ¾ú½À´Ï´Ù°í º¸°íÇß½À´Ï´Ù. °¨¿°Áõ(CAUTI)À²Àº 28.01% °¨¼ÒÇß½À´Ï´Ù. Á߽ɼ± °ü·Ã Ç÷·ù °¨¿°(CLABSI) ºñÀ²Àº 37.61% °¨¼ÒÇß½À´Ï´Ù. ¼ö¼ú ºÎÀ§ °¨¿°(SSI) ºñÀ²Àº 62.39% °¨¼ÒÇßÀ¸¸ç ÀΰøÈ£Èí±â °ü·Ã Æó·Å(VAP) ºñÀ²ÀÌ °¡Àå ³ô¾Ò´ø °ÍÀº 2019³â 11¿ùÀ̾ú½À´Ï´Ù. µû¶ó¼ °¨¿°À» ÅëÁ¦Çϱâ À§ÇÑ COVID-19¿¡ ´ëÇÑ ¿¹¹æÁ¶Ä¡°¡ ±¤¹üÀ§ÇÏ°Ô °±¸µÊ¿¡ µû¶ó HAIµµ °¨¼ÒÇß½À´Ï´Ù. ÀûÀýÇÑ À§»ý »óŸ¦ À¯ÁöÇÏ°í °¨¿°À» ¹æÁöÇϱâ À§ÇØ °ü¸® Á¶Ä¡°¡ ¾ö°ÝÇÏ°Ô ÁؼöµÇ¾ú½À´Ï´Ù. µû¶ó¼ COVID-19´Â ½ÃÀå ¼ºÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù.
½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ±¸Ã¼ÀûÀÎ ¿äÀÎÀº ¸¸¼º Áúȯ°ú ¼ö¼ú·Î ÀÎÇÑ ÀÔ¿ø ±â°£ Áõ°¡¸¦ Æ÷ÇÔÇÕ´Ï´Ù. ´Ù¾çÇÑ À¯ÇüÀÇ º´¿ø³» °¨¿° ¹ß»ý·ü Áõ°¡. °¨¿°À» Á¦¾îÇÏ´Â ÀåÄ¡¿¡ ±¸ÇöµÈ Çõ½ÅÀûÀÎ ±â¼ú.
º´¿ø³» °¨¿°Àº ÀϹÝÀûÀ¸·Î ½Åü¿¡¼ ºü¸£°Ô È®»êµÇ´Â º´¿øÃ¼¿¡ ÀÇÇØ ¹ß»ýÇÕ´Ï´Ù. ȯÀÚÀÇ ¸é¿ª·ÂÀÌ ¾àÇÏ°í º´¿ø ³»ÀÇ È¯°æµµ ¿¾ÇÇϱ⠶§¹®¿¡ °¨¿°Àº ¸¸¼º °¨¿°º¸´Ù »¡¸® ÆÛÁý´Ï´Ù. Áúº´°ü¸®¿¹¹æ¼¾ÅÍÀÇ ÇコÄÉ¾î °ü·Ã °¨¿° ÁøÇà º¸°í¼ 2020¿¡ µû¸£¸é 2020³â ¹Ì±¹¿¡¼ º¸°íµÈ ¼ö¼ú ºÎÀ§ °¨¿°Àº 18,416°Ç °¡±îÀÌ ÀÖ¾ú½À´Ï´Ù. ¶ÇÇÑ, ÀÌ Áß 6.094°ÇÀÇ °¨¿°Àº °áÀå ¼ö¼ú Áß¿¡ ¹ß»ýÇÏ¿´°í, 2,173°ÇÀº °í°üÀý ¼ºÇü¼ú Áß¿¡ ¹ß»ýÇß´Ù°í º¸°íÇÏ¿´½À´Ï´Ù. ÀÌ¿Í °°ÀÌ ¼ö¼ú ºÎÀ§ÀÇ °¨¿°·üÀÌ ³ô±â ¶§¹®¿¡ HAI¸¦ Á¦¾îÇÏ´Â Á¦Ç°ÀÇ Çʿ伺ÀÌ »ý°Ü ½ÃÀåÀÇ ¼ºÀåÀÌ ÃËÁøµË´Ï´Ù.
¼¼°è ½ÃÀå °ü°èÀÚµéÀÇ Á¦Ç° Ãâ½Ãµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 5¿ù¿¡ ¿¡½ºÄÚ´Â °í¿ ¸ê±Õ ±â´ÉÀ» °®Ãá Esco CelCulture CO2 ÀÎÅ¥º£ÀÌÅÍ(CCL-HHS)¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ½ÅÁ¦Ç°Àº 180¡ÆC °Ç¿ ¸ê±Õ ½Ã½ºÅÛÀ» äÅÃÇÏ¿© ÀÛ¾÷ °ø°£À» ¿À¿°½Ãų ¼ö ÀÖ´Â º¸Åë ³»¼º °õÆÎÀÌ, ¹ÚÅ׸®¾Æ Æ÷ÀÚ ¹× ¿µ¾ç ¼¼Æ÷¸¦ Á×ÀÌ´Â µ¥ È¿°úÀûÀÓÀ» ÀÔÁõÇÕ´Ï´Ù. µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ Ãâ½Ã´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.
¶ÇÇÑ 2021³â 11¿ù PURioLABS´Â ¼ºñ½º ÇöÀå¿¡¼ ÀÚÁÖ Á¢ÃËÇÏ´Â Àåºñ ¹× Àåºñ¿¡ ºÎÂøµÈ °¨¿° ¹Ì»ý¹°À» ÆÄ±«Çϰí ÀÇ·á °ü·Ã °¨¿°(HAI)À» ¹æÁöÇϵµ·Ï ¼³°èµÈ °í¼öÁØ ÈÞ´ë¿ë ¼Òµ¶ ijºñ´Ö PURitALL ¸¦ °³¹ßÇß½À´Ï´Ù. ÀÌ·¯ÇÑ Ãâ½Ã´Â ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÕ´Ï´Ù.
µû¶ó¼ À§ÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÀ» ¿¹ÃøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª º´¿ø³» °¨¿°¿¡ ´ëÇÑ ÀÎ½Ä ºÎÁ·°ú ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀº ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.
¼Òµ¶Àº ¹«»ý¹°¿¡¼ ¹ÚÅ׸®¾Æ Æ÷ÀÚ¸¦ Á¦¿ÜÇÑ º´¿ø¼º ¹Ì»ý¹°ÀÇ ´ëºÎºÐ ¶Ç´Â ÀüºÎ¸¦ Á¦°ÅÇÏ´Â °úÁ¤ÀÔ´Ï´Ù. À̰ÍÀº ¾×ü ÈÇÐ ¹°ÁúÀÇ »ç¿ë ¶Ç´Â ½À½Ä Àú¿Â »ì±Õ¿¡ ÀÇÇØ ½ÇÇöµË´Ï´Ù. ¼Òµ¶ÀÇ È¿À²Àº ¿©·¯ ¿äÀÎÀÇ ¿µÇâÀ» ¹ÞÀ¸¸ç, °¢°¢Àº °øÁ¤ÀÇ È¿°ú¸¦ Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù.
º´¿ø³» °¨¿°ÀÇ ¹ß»ý·ü Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡, À̾îÁö´Â ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡ ¹× ¼ö¼ú °Ç¼ö Áõ°¡°¡ ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» ÃßÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¡¸ÀÇ·á°ü·Ã °¨¿°Áõ : ÀÇ·áÇöÀå¿¡¼ÀÇ »õ·Î¿î º´¸®ÇС¹À̶ó´Â Á¦¸ñÀÇ ¿¬±¸¿¡ ÀÇÇϸé, 2020³â 2¿ù¿¡ ¹ßÇ¥µÈ ³í¹®¿¡ ÀÇÇϸé, º´¿ø³» °¨¿°ÀÇ ¾à 50%´Â ÁýÁß Ä¡·á½Ç¿¡¼ ¹ß»ýÇϰí ÀÖ½À´Ï´Ù. Ç¥¸é ¼Òµ¶Á¦´Â ÀÌ·¯ÇÑ °¨¿°À» ¿¹¹æÇϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϱ⠶§¹®¿¡ °¡±î¿î ¹Ì·¡¿¡ ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀÔ´Ï´Ù.
¶ÇÇÑ ½ÃÀå °ü°èÀÚÀÇ ½ÅÁ¦Ç° Ãâ½Ãµµ ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 4¿ù¿¡ ITC´Â ÀÚ»ç Á¦Ç°ÀÎ Savlon Surface Disinfectant Spray¸¦ Ãâ½ÃÇß½À´Ï´Ù. ¶ÇÇÑ 2022³â 2¿ù SC Á¸½¼ ÇÁ·ÎÆä¼Å³ÎÀº °è·®ÇÏ°í ¾ÐÂøÇÏ°í ½ñ¾ÆÁö±â ½¬¿î »õ·Î¿î º´ÀÇ Á¦4 ¼ººÐ ¼Òµ¶ Ŭ¸®³Ê¸¦ ºÏ¹Ì¿¡¼ Ãâ½ÃÇß½À´Ï´Ù. µû¶ó¼ ½ÅÁ¦Ç° Ãâ½Ãµµ ½ÃÀå ºÎ¹® ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
µû¶ó¼ À§ÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ½ÃÀå ¼Òµ¶Á¦ ºÎ¹®ÀÌ ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ºÏ¹Ì´Â ¸¸¼ºÁúȯ°ú ¼ö¼ú¿¡ ÀÇÇÑ ÀÔ¿ø±â°£ Áõ°¡, ÀÔ¿øÀÚ¼ö Áõ°¡, °¨¿°À» Á¦¾îÇÏ´Â ±â±â¿¡ µµÀÔµÈ Çõ½ÅÀûÀÎ ±â¼ú°ú ÇÔ²² º´¿ø³» °¨¿° ºÎ´ã Áõ°¡·Î Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ´Ù ÇÕ´Ï´Ù. ±âŸ.
¹Ì±¹ Áúº´°ü¸®¿¹¹æ¼¾ÅÍ¿¡ µû¸£¸é 2021³â¿¡´Â 2019³âºÎÅÍ 2020³â »çÀÌ¿¡ Á߽ɼ±Ç÷·ù °¨¿°Áõ(CLABSI)ÀÌ ¾à 24% Áõ°¡Çϰí ÀΰøÈ£Èí±â °ü·Ã À̺¥Æ®(VAE)°¡ 35% Áõ°¡ ¿¹»óµË´Ï´Ù. ±×·¯¹Ç·Î ¹Ì±¹¿¡¼ º´¿ø³» °¨¿°ÀÇ À¯º´·ü Áõ°¡´Â ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀ» ¹Ð¾î ¿Ã¸®°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ ½ÉÇ÷°ü Áúȯ°ú ¾Ï µî ¸¸¼º Áúȯ Áõ°¡·Î Àå±â ÀÔ¿ø°ú ¼ö¼úÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹ º¸°ÇÇùȸÀÇ 2022³â µ¥ÀÌÅÍ¿¡ µû¸£¸é 2022³â ÀÔ¿øÀÚ ¼ö´Â ¾à 3,335¸¸ 6,853¸íÀ̾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÔ¿øÀÚÀÇ ´ëºÎºÐÀº ¸¸¼º Áúȯ°ú ½ÉÀå ¿ìȸ ¼ö¼ú°ú °°Àº Áß¿äÇÑ Ä¡·á·Î ÀÎÇÑ °ÍÀ̾ú½À´Ï´Ù. µû¶ó¼ ÀÔ¿øÀÚ ¼ö°¡ Áõ°¡ÇÏ¸é °¨¿°Á¦¾îÁ¦Ç°ÀÇ Çʿ伺ÀÌ ¹ß»ýÇÏ¿© ÀÌ Áö¿ª ½ÃÀåÀÌ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¶ÇÇÑ 2021³â 2¿ù Penn MedicineÀº ¹Ì±¹ Çʶóµ¨ÇÇ¾Æ ³²¼ºÎ¿¡ ÃÖ´ë ±Ô¸ðÀÇ ±â±¸ ó¸® ¹× ¼ö¼ú Áغñ ½Ã¼³ Áß ÇϳªÀÎ »õ·Î¿î °³ÀÔ Áö¿ø ¼¾ÅÍ(ISC)¸¦ °³¼³Çß½À´Ï´Ù. ISC´Â Ææ½Çº£´Ï¾Æ¿¡¼ ÀÌ·± À¯ÇüÀÇ ½Ã¼³·Î¼ ÃÖÃÊÀÇ ½Ã¼³ Áß Çϳª·Î, Á÷¿øÀº ¸ÅÀÏ ±âº»ÀûÀÎ °¡À§¿Í Ŭ·¥ÇÁ¿¡¼ °í±Þ ·Îº¿ ±â±¸¿¡ À̸£±â±îÁö ¼ö¼ú°ú óġ¿¡ ´ëºñÇÏ¿© ¼öõ °³ÀÇ ±â±¸¸¦ ¸ê±Õ ÇÏ°í Æ÷ÀåÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ½Ã¼³ÀÇ ¼³¸³µµ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.
µû¶ó¼ À§ÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ Á¶»ç ´ë»óÀÌ µÈ ºÏ¹Ì ½ÃÀåÀº ¿¹Ãø±â°£ µ¿¾È Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º´¿ø ³» °¨¿° ´ëÃ¥ ½ÃÀåÀº °æÀïÀÌ ½ÉÇÏ°í ¿©·¯ ±â¾÷À¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. 3M Company, Becton, Dickinson and Company, Belimed AG, Biomerieux Sa, Cantel Medical, Ethicon, Getinge Group, Kimberly-Clark Corporation, Sterigenics International LLC, Steris Corporation µîÀÇ ±â¾÷µéÀÌ º´¿ø¿¡¼ »ó´çÇÑ ½ÃÀå Á¡À¯À²À» º¸À¯Çϰí ÀÖ½À´Ï´Ù.
The Global Hospital Acquired Infection Control Market size is estimated at USD 4.26 billion in 2024, and is expected to reach USD 5.18 billion by 2029, growing at a CAGR of 3.97% during the forecast period (2024-2029).
The COVID-19 pandemic underlined the critical necessity of hand hygiene and the use of conventional infection control methods, as the World Health Organization and the Centers for Disease Control and Prevention (CDC) recommended, in reducing the number of hospital-acquired infections. Additionally, the article titled "Prevention of hospital-acquired infections: A construct during Covid-19 pandemic" published in September 2021, reported that in the Bihar state of India, data was collated from January 2019 to December 2020, catheter-associated urinary tract infections (CAUTI) rates were reduced by 28.01%; the central-line-associated bloodstream infections (CLABSI) rates declined by 37.61%; the surgical site infections (SSIs) rates were reduced by 62.39%, while the highest ventilator-associated pneumonia (VAP) rates were reported in November 2019. Thus, due to widespread precautions against COVID-19 to control infection, HAI was also reduced. Although to maintain the proper hygienic conditions and prevent infection, control measures were stringently followed. Thus, COVID-19 had a significant impact on the growth of the market.
Specific factors driving the market's growth include increased hospital stays due to chronic diseases and surgeries; a rise in the incidences of different types of hospital-acquired infections; and innovative technologies implemented in devices that control infection.
Hospital-acquired infections are usually caused by pathogens, which spread quickly in the body. Due to the patients' weak immune systems and poor conditions in a hospital, infections spread faster than chronic infections. According to the Centers for Disease Control and Prevention, Healthcare Associated Infection Progress Report 2020, there were nearly 18,416 surgical site infections reported in 2020 in the United States. It also reported that out of this 6.094 infections were during colon surgery and 2,173 occurred during hip arthroplasty. Such a high rate of surgical site infection creates the need for products to control HAIs and thus propels the growth of the market.
The launch of products by market players around the globe is also contributing to the growth of the market. For instance, in May 2020, Esco launched the Esco CelCulture CO2 Incubator with High Heat Sterilization (CCL-HHS). This new product adopts a 180°C dry heat sterilization system, proven effective in killing normally resistant fungi, bacterial spores, and vegetative cells that may contaminate the workspace. Such launches are expected to propel the growth of the market.
Furthermore, in November 2021, PURioLABS developed PURitALL, a high-level, portable disinfection cabinet designed to destroy infection microbes on high-touch equipment and supplies at the point of service and to prevent healthcare-associated infections (HAIs). Such launches drive the growth of the market.
Thus, owing to the abovementioned factors, the market is expected to project growth over the forecast period. However, a lack of awareness regarding hospital-acquired infections and stringent regulatory requirements may hinder the growth of the market.
Disinfection is a process that eliminates many or all pathogenic microorganisms, except bacterial spores, from inanimate objects. This is accomplished by the use of liquid chemicals or wet pasteurization. The efficiency of disinfection has been affected by several factors, each of which may limit the efficacy of the process.
The rising incidence of hospital-acquired infections, a growing geriatric population, and subsequent growth in the prevalence of chronic diseases and the increasing number of surgical procedures are expected to drive the segment growth. As per the study titled "Healthcare-Associated Infections: A New Pathology in Medical Practice?" published in February 2020, about 50% of hospital-acquired infections occur in the intensive care unit. Surface disinfectants play a crucial role in preventing these infections, thus will boost the segment growth in the near future.
Additionally, the launch of new products by the market players is also propelling the growth of the segment. For instance, in April 2020, ITC launched its product Savlon Surface Disinfectant Spray. Also, in February 2022, SC Johnson Professional launched its Quaternary Disinfectant Cleaner in a new easy-to-measure, squeeze and pour the bottle in North America. Thus, the launch of new products is also expected to contribute to the growth of the market segment.
Thus, owing to the abovementioned factors, the disinfectant segment of the market is expected to grow over the forecast period.
North America is expected to hold a significant share owing to the increase in hospital stays due to chronic diseases and surgeries, the rising number of hospital admission, the increasing burden of hospital-acquired infection coupled with the innovative technologies implemented in devices that control infection, and others.
According to the Center for Disease Control and Prevention, in 2021, about a 24% increase in central line bloodstream infection (CLABSI) and a 35% increase in Ventilator-Associated Event (VAE) between 2019-2020. Thus, the increasing prevalence rate of hospital-acquired infections in the United States boosts the market growth in the region.
Additionally, the rise in chronic diseases such as cardiovascular diseases, cancer, and others requires extended hospital stays and surgeries. For instance, according to 2022 data by the American Health Association, there were approximately 33,356,853 hospital admissions in 2022. Many of these admissions were due to chronic diseases and critical procedures like heart bypass surgery. Thus, the increasing number of hospital admissions is expected to create the need for infection control products and thereby boost the market in the region.
Additionally, in February 2021, Penn Medicine opened its new Interventional Support Center (ISC), one of the largest instrument processing and surgical supply preparation facilities in Southwest Philadelphia, United States. The ISC is one of the first facilities of its kind in Pennsylvania where staff will both sterilize and package thousands of instruments each day in preparation for surgeries and procedures, from basic scissors and clamps to advanced robotic instruments. The establishment of such facilities is also expected to propel the growth of the market.
Thus, owing to the abovementioned factors, the studied market in the North American region is expected to project significant growth over the forecast period.
The hospital-acquired infection control market is highly competitive and consists of several players. Companies like 3M Company, Becton, Dickinson and Company, Belimed AG, Biomerieux Sa, Cantel Medical, Ethicon, Getinge Group, Kimberly-Clark Corporation, Sterigenics International LLC, and Steris Corporation, among others, hold a substantial market share in the hospital-acquired infection control market.